Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Rivaroxaban in Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02072668
Recruitment Status : Completed
First Posted : February 26, 2014
Last Update Posted : February 11, 2019
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : December 31, 2018